17 / 35
Precision immunotherapy
•
For some NSCLC patients this treatment is truly life changing.
•
However, these durable effects have only been demonstrated in a subset of
patients
•
Key next steps are
–
To identify the patients most likely to benefit.
–
To understand mechanisms of resistance
100
75
50
25
0
6
18
9
3
0
12 15
21
100
75
50
25
0
6
18
9
3
PFS (%)
0
12 15
24
21
High TMB,
PD-L1 ≥50%
High TMB,
PD-L1 1–49%
Low/medium TMB,
PD-L1 1–49%
Low/medium TMB,
PD-L1 ≥50%
Low/medium TMB,
PD-L1 ≥50%
High TMB,
PD-L1 1–49%
Low/mediu
m TMB,
PD-L1 1–
49%
High TMB,
PD-L1 ≥50%
Nivolumab Arm
Chemotherapy Arm